- Home
- CMPO vs LQDA Comparison
CMPO vs LQDA Comparison
Compare CMPO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- LQDA
- Stock Information
- Founded
- CMPO 2000
- LQDA 2004
- Country
- CMPO United States
- LQDA United States
- Employees
- CMPO N/A
- LQDA N/A
- Industry
- CMPO Finance: Consumer Services
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- LQDA Health Care
- Exchange
- CMPO Nasdaq
- LQDA Nasdaq
- Market Cap
- CMPO 2.1B
- LQDA 1.9B
- IPO Year
- CMPO N/A
- LQDA 2018
- Fundamental
- Price
- CMPO $19.79
- LQDA $23.77
- Analyst Decision
- CMPO Strong Buy
- LQDA Strong Buy
- Analyst Count
- CMPO 6
- LQDA 9
- Target Price
- CMPO $18.83
- LQDA $32.67
- AVG Volume (30 Days)
- CMPO 663.6K
- LQDA 2.7M
- Earning Date
- CMPO 11-07-2025
- LQDA 11-12-2025
- Dividend Yield
- CMPO N/A
- LQDA N/A
- EPS Growth
- CMPO N/A
- LQDA N/A
- EPS
- CMPO N/A
- LQDA N/A
- Revenue
- CMPO $267,817,999.00
- LQDA $19,322,000.00
- Revenue This Year
- CMPO $10.30
- LQDA $405.58
- Revenue Next Year
- CMPO $8.12
- LQDA $373.93
- P/E Ratio
- CMPO N/A
- LQDA N/A
- Revenue Growth
- CMPO N/A
- LQDA 30.20
- 52 Week Low
- CMPO $9.24
- LQDA $9.71
- 52 Week High
- CMPO $21.00
- LQDA $29.94
- Technical
- Relative Strength Index (RSI)
- CMPO 50.15
- LQDA 50.77
- Support Level
- CMPO $19.06
- LQDA $22.14
- Resistance Level
- CMPO $20.89
- LQDA $24.65
- Average True Range (ATR)
- CMPO 0.69
- LQDA 1.26
- MACD
- CMPO -0.15
- LQDA 0.12
- Stochastic Oscillator
- CMPO 39.85
- LQDA 64.19
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.